MGMT and glioblastoma: Treatment-specific studies also failed to identify differences between most pairs of treatment, including for lomustine-TMZ versus TMZ monotherapy in patients with MGMT-methylated glioblastoma (59) or lomustine versus the tyrosine kinase inhibitor regorafenib in patients with recurrent glioblastoma (58).